Psychoeducative Treatment of FEP With Mobile Training. ThinkApp

May 26, 2025 updated by: International University of La Rioja

Psychoeducative Treatment of First Episode Psychosis With Mobile Training (ThinkApp):Study Protocol for a Randomised Controlled Trial

The aim of the study is to evaluate the effectiveness of an online intervention through a mobile application, specifically designed for adolescents with a First Psychotic Episode (FEP), as a complement to the pharmacological and therapeutic interventions they receive at their referral center (Treatment as usual). To do this, a longitudinal study will be carried out on patients with FEP and between the ages of 14 and 30, who come to the Child and Adolescent Psychiatry Service of the General Universitarian Hospital "Gregorio Marañón", Psychiatry Department of the Ramon y Cajal Hospital in Madrid and Psychiatry Department of San Joan de Déu in Catalonia. Adolescents and young will be randomly assigned to an experimental group, where they will receive standard treatment plus online intervention, or a control group, where they will receive standard treatment.

This online intervention, the continuation of the work of this same team researcher in the "PIENSA program", aims to address little of the more traditional treatments and treatments such as community functioning, quality of life or affective symptoms. In addition, it will increase disease awareness, which will lead to greater adherence to treatment and fewer relapses and rehospitalizations.

Study Overview

Detailed Description

Clinical assessment criteria Data on the major clinical and demographic variables are entered in a data collection form. All patients are assessed at baseline and have been or will be assessed at 3 months and at 6 months after inclusion in the study. All the instruments used in the study have demonstrated appropriate psychometric properties, and were used in many studies

Demographic data Data are collected on age, sex, level of education, living arrangements and employment or educational status.

Assessment of psychotic symptoms are assessed using the Positive and Negative Syndrome Scale. The scale for the assessment of positive symptoms and negative symptoms. Trait and state anxiety will be measured using the State-Trait Anxiety Inventory. The mood is evaluated using the Hamilton Rating Scale for Depression. We measure patient insight into their illness using the Scale to Assess Unawareness of Mental Disorders. We use the Strauss and Carpenter Prognostic Scale. We also assess the overall function of patients using a Spanish version of the Global Assessment of Functioning Scale. The level of functioning was measured using the Children's Global Assessment Scale. We measure this variable using the "Morisky" Medication Adherence Scale. We measure patient functional status using the Functioning Assessment Short Test.

The consumption is measured using the ASI (Addition severity index) scale. The quality of life is measured using the World Health Organization Quality of Life WHOQOL-BREF Questionnaire .In addition, we assess quality of life using the EuroQoL questionnaire.

Mobile Application Android/Ios Mobile app with a web support and administration application, along with a cloud based backend database, which will register fine-grain interactions between the users and the app, in order to make possible the generation of relevant granular data and key performance indicators to support a wide range of further analysis.

This application will be designed and developed using Software Engineering-based Agile Methodologies, under SCRUM principles (empiric control of the development process, using continuous feedback processes). The whole mobile app functionality and its user interfaces and interactions will be designed under the premises of maximizing the User experience, as a factor contributing to the adherence of users to the treatment.

On the security side, all of the communications between the mobile app and the supporting backend will be protected by means of a "SSL" digital certificate on the server, providing end to end encrypted communications

Data Management For security, all data introduce in database will have an internal code, and will be checked by another data manager, in order to guarantee the data security.

Intervention programme

Mobile phone App treatment

The psychoeducational app programme is composed of 5 modules:

  • Psychoeducative Module (12 sessions)
  • Module of recognition of symptomatology and prevention of relapses
  • Module Troubleshooting
  • Mindfulness Module
  • Module of social skills

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain
        • Ana Belén Calvo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 19 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age of the patient between 14-30 years
  • The presence of at least 1 positive psychotic symptom (delusions or hallucinations) and 1 of the following diagnoses from DSM-5 (Apa., 2013): schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, major depressive disorder with psychotic features, brief psychotic disorder, or psychosis not otherwise specified.
  • Be at least two months without presenting acute psychotic symptoms (delusions or hallucination).
  • Written consent given by the patient, parents and / or legal representative.(n this case they must accept to participate both, minor and tutor, concretely, the minors since from the age of 14 also have to accept to participate. )
  • Access to a smartphone

Exclusion Criteria:

  • Abuse and dependence on toxicants (use is accepted).
  • Presence of organic diseases of the central nervous system, mental retardation or generalized developmental disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental group
Mobile psychotherapy (5 modules) plus treatment as usual
The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
Other Names:
  • Psychotherapy group (5 modules)
Other: Control group

Control group: Treatment as usual

The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention

Group that does not receive any treatment added to its usual treatment
Other Names:
  • Control group, or treatment as usual group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in psychotic symptoms
Time Frame: Change from Baseline psychotic symptoms at 3 months
Assessment of psychotic symptoms are assessed using the Positive and Negative Syndrome Scale
Change from Baseline psychotic symptoms at 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in affective symptoms
Time Frame: Change from baseline affective symptoms at 3 months
The mood was evaluated using the Hamilton Rating Scale for Depression
Change from baseline affective symptoms at 3 months
Change from Baseline in anxiety level
Time Frame: Change from baseline anxiety symptoms at 3 months
Anxiety is measured using the State-Trait Anxiety Inventory
Change from baseline anxiety symptoms at 3 months
Change From Baseline in functionality
Time Frame: Change from Baseline functionality at 3 months
The functionality is measure using Children's Global Assessment Scale
Change from Baseline functionality at 3 months
Change From Baseline in functionality II
Time Frame: Change from baseline functionality at 3 months
The functionality is measure using Global Assessment of Functioning Scale
Change from baseline functionality at 3 months
Change From Baseline in functionality III
Time Frame: Change from baseline functionality at 3 months
The functionality is measure using Strauss Carpenter Rating Scale
Change from baseline functionality at 3 months
Change from baseline in prognosis I
Time Frame: Change from baseline prognosis at 3 months
Number of relapses, hospitalizations and visits to the ER.
Change from baseline prognosis at 3 months
Change from baseline in drug´s use
Time Frame: Change from baseline drug´s use at 3 months
The consumption is measured using the ASI (ASI-6 scale)
Change from baseline drug´s use at 3 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in adherence
Time Frame: Change from baseline adherence level at 3 months
The adherence is measured using Morisky Medication Adherence Scale
Change from baseline adherence level at 3 months
Change from baseline in quality of life
Time Frame: Change from baseline quality of life at 3 months
The quality of life is measured using the World Health Organization Quality of Life WHOQOL
Change from baseline quality of life at 3 months
Change from baseline in quality of life II
Time Frame: Change from baseline quality of life at 3 months
The quality of life is measured using EuroQoL scale
Change from baseline quality of life at 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ana Calvo, PI, UNIR

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

May 13, 2025

Study Completion (Actual)

May 13, 2025

Study Registration Dates

First Submitted

May 2, 2017

First Submitted That Met QC Criteria

May 17, 2017

First Posted (Actual)

May 19, 2017

Study Record Updates

Last Update Posted (Actual)

May 28, 2025

Last Update Submitted That Met QC Criteria

May 26, 2025

Last Verified

May 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychosis

Clinical Trials on Experimental group

Subscribe